Author:
Millar Jonathan E.,Craven Thomas H.,Shankar-Hari Manu
Reference110 articles.
1. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes;Bos;Lancet Lond Engl,2022
2. Estimating the attributable fraction of mortality from acute respiratory distress syndrome to inform enrichment in future randomised clinical trials;Saha;Thorax,2023
3. Pharmacological agents for adults with acute respiratory distress syndrome;Lewis;Cochrane Database Syst Rev,2019
4. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial;Marconi;Lancet Respir Med,2021
5. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial;Lancet Lond Engl,2021